Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
Dennie MeijerBernard H E JansenMaurits WondergemYves J L BodarSandra SrbljinAnnelies E VellekoopBram KeizerFriso M van der ZantOtto S HoekstraJakko A NieuwenhuijzenMax DaheleAndré N VisDaniela E Oprea-LagerPublished in: PloS one (2020)
In this study, the clinical verification of 18F-DCFPyL PET-positive lesions in patients with BCR was performed. Diagnostic certainty of PET-detected lesions increases in the presence of characteristic abnormalities on CT, when SUVpeak is ≥3.5, when PSA-levels exceed 2.0 ng/mL or in patients with more than two PET-positive lesions.